Hmga1‐overexpressing lentivirus protects against osteoporosis by activating the Wnt/β‐catenin pathway in the osteogenic differentiation of BMSCs

Postmenopausal osteoporosis is associated with bone formation inhibition mediated by the impaired osteogenic differentiation potential of bone marrow mesenchymal stem cells (BMSCs). However, identifying and confirming the essential genes in the osteogenic differentiation of BMSCs and osteoporosis remain challenging. The study aimed at revealing the key gene that regulated osteogenic differentiation of BMSCs and led to osteoporosis, thus exploring its therapeutic effect in osteoporosis. In the present study, six essential genes related to the osteogenic differentiation of BMSCs and osteoporosis were identified, namely, fibrillin 2 (Fbn2), leucine‐rich repeat‐containing 17 (Lrrc17), heat shock protein b7 (Hspb7), high mobility group AT‐hook 1 (Hmga1), nexilin F‐actin‐binding protein (Nexn), and endothelial cell‐specific molecule 1 (Esm1). Furthermore, the in vivo and in vitro experiments showed that Hmga1 expression was increased during the osteogenic differentiation of rat BMSCs, while Hmga1 expression was decreased in the bone tissue of ovariectomized (OVX) rats. Moreover, the expression of osteogenic differentiation‐related genes, the activity of alkaline phosphatase (ALP), and the number of mineralized nodules were increased after Hmga1 overexpression, which was partially reversed by a Wnt signaling inhibitor (DKK1). In addition, after injecting Hmga1‐overexpressing lentivirus into the bone marrow cavity of OVX rats, the bone loss, and osteogenic differentiation inhibition of BMSCs in OVX rats were partially reversed, while osteoclast differentiation promotion of BMSCs in OVX rats was unaffected. Taken together, the present study confirms that Hmga1 prevents OVX‐induced bone loss by the Wnt signaling pathway and reveals that Hmga1 is a potential gene therapeutic target for postmenopausal osteoporosis.

[1]  Y. Xiong,et al.  Circulating MiRNA-21-enriched extracellular vesicles promote bone remodeling in traumatic brain injury patients , 2023, Experimental & Molecular Medicine.

[2]  Sien Lin,et al.  Hallmarks of peripheral nerve function in bone regeneration , 2023, Bone Research.

[3]  Y. Hu,et al.  The role of the immune microenvironment in bone, cartilage, and soft tissue regeneration: from mechanism to therapeutic opportunity , 2022, Military Medical Research.

[4]  shanliang song,et al.  Nanozyme-reinforced hydrogel as a H2O2-driven oxygenerator for enhancing prosthetic interface osseointegration in rheumatoid arthritis therapy , 2022, Nature Communications.

[5]  Zhaojian Liu,et al.  Overexpression of HMGA1 confers radioresistance by transactivating RAD51 in cholangiocarcinoma , 2021, Cell death discovery.

[6]  T. Hügle,et al.  CD11b Signaling Prevents Chondrocyte Mineralization and Attenuates the Severity of Osteoarthritis , 2020, Frontiers in Cell and Developmental Biology.

[7]  Dongwei Fan,et al.  CMTM3 suppresses bone formation and osteogenic differentiation of mesenchymal stem cells through inhibiting Erk1/2 and RUNX2 pathways , 2020, Genes & diseases.

[8]  Z. Tang,et al.  HSPB7 regulates osteogenic differentiation of human adipose derived stem cells via ERK signaling pathway , 2020, Stem cell research & therapy.

[9]  Wenjie Gao,et al.  Melatonin promotes bone marrow mesenchymal stem cell osteogenic differentiation and prevents osteoporosis development through modulating circ_0003865 that sponges miR-3653-3p , 2020, Stem cell research & therapy.

[10]  Ge Zhang,et al.  Targeted silencing of miRNA-132-3p expression rescues disuse osteopenia by promoting mesenchymal stem cell osteogenic differentiation and osteogenesis in mice , 2020, Stem Cell Research & Therapy.

[11]  Liangcong Hu,et al.  Circulating Exosomal miR-20b-5p Inhibition Restores Wnt9b Signaling and Reverses Diabetes-Associated Impaired Wound Healing. , 2019, Small.

[12]  Qianqian Wang,et al.  The Prevalence of Osteoporosis in China, a Nationwide, Multicenter DXA Survey , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  H. Kampinga,et al.  The N terminus of the small heat shock protein HSPB7 drives its polyQ aggregation–suppressing activity , 2019, The Journal of Biological Chemistry.

[14]  M. Lorentzon.  Treating osteoporosis to prevent fractures: current concepts and future developments , 2019, Journal of internal medicine.

[15]  Lana S. Martin,et al.  How bioinformatics and open data can boost basic science in countries and universities with limited resources , 2019, Nature Biotechnology.

[16]  T. Martin,et al.  Antiresorptive and anabolic agents in the prevention and reversal of bone fragility , 2019, Nature Reviews Rheumatology.

[17]  T. Yuen,et al.  Emerging concepts in the epidemiology, pathophysiology, and clinical care of osteoporosis across the menopausal transition. , 2018, Matrix biology : journal of the International Society for Matrix Biology.

[18]  T. Evans,et al.  Hspb7 is a cardioprotective chaperone facilitating sarcomeric proteostasis. , 2018, Developmental biology.

[19]  Roberta B. Nowak,et al.  HSPB7 is indispensable for heart development by modulating actin filament assembly , 2017, Proceedings of the National Academy of Sciences.

[20]  L. Cope,et al.  HMGA1 amplifies Wnt signalling and expands the intestinal stem cell compartment and Paneth cell niche , 2017, Nature Communications.

[21]  Yanhua Cao,et al.  HMGA1 facilitates tumor progression through regulating Wnt/β-catenin pathway in endometrial cancer. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[22]  Yan Jin,et al.  TNF‐α Inhibits FoxO1 by Upregulating miR‐705 to Aggravate Oxidative Damage in Bone Marrow‐Derived Mesenchymal Stem Cells during Osteoporosis , 2016, Stem cells.

[23]  Yan Jin,et al.  MiR-26a Rescues Bone Regeneration Deficiency of Mesenchymal Stem Cells Derived From Osteoporotic Mice. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  G. Ameer,et al.  Bone morphogenetic protein-9 effectively induces osteogenic differentiation of reversibly immortalized calvarial mesenchymal progenitor cells☆ , 2015, Genes & diseases.

[25]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[26]  Cheng-Wen Wang,et al.  Influence of glucocorticoids on the osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells , 2014, BMC Musculoskeletal Disorders.

[27]  E. Canalis.  Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches , 2013, Nature Reviews Endocrinology.

[28]  L. Liao,et al.  Redundant miR-3077-5p and miR-705 mediate the shift of mesenchymal stem cell lineage commitment to adipocyte in osteoporosis bone marrow , 2013, Cell Death and Disease.

[29]  Roland Baron,et al.  WNT signaling in bone homeostasis and disease: from human mutations to treatments , 2013, Nature Medicine.

[30]  Sean R. Davis,et al.  NCBI GEO: archive for functional genomics data sets—update , 2012, Nucleic Acids Res..

[31]  B. Sacchetti,et al.  Stem cells in skeletal physiology and endocrine diseases of bone. , 2011, Endocrine development.

[32]  T. Rachner,et al.  Osteoporosis: now and the future , 2011, The Lancet.

[33]  Di Chen,et al.  Psoralen stimulates osteoblast differentiation through activation of BMP signaling. , 2011, Biochemical and biophysical research communications.

[34]  Jason C. Ho,et al.  Faculty Opinions recommendation of Extracellular microfibrils control osteoblast-supported osteoclastogenesis by restricting TGF{beta} stimulation of RANKL production. , 2010 .

[35]  G. Karsenty,et al.  Fibrillin-1 and -2 differentially modulate endogenous TGF-β and BMP bioavailability during bone formation , 2010, The Journal of cell biology.

[36]  F. Ramirez,et al.  Extracellular Microfibrils Control Osteoblast-supported Osteoclastogenesis by Restricting TGFβ Stimulation of RANKL Production* , 2010, The Journal of Biological Chemistry.

[37]  H. So,et al.  Identification of LRRc17 as a Negative Regulator of Receptor Activator of NF-κB Ligand (RANKL)-induced Osteoclast Differentiation* , 2009, Journal of Biological Chemistry.

[38]  J. Shaughnessy,et al.  The role of Dickkopf-1 in bone development, homeostasis, and disease. , 2009, Blood.

[39]  Andrea Giustina,et al.  Mechanisms of anabolic therapies for osteoporosis. , 2007, The New England journal of medicine.

[40]  Mone Zaidi,et al.  Skeletal remodeling in health and disease , 2007, Nature Medicine.

[41]  D. Bauer,et al.  Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. , 2005, Endocrine reviews.

[42]  G. Manfioletti,et al.  HMGA molecular network: From transcriptional regulation to chromatin remodeling. , 2010, Biochimica et biophysica acta.